Effect of dopamine receptor agonists on treatment-resistant depression

Effect of dopamine receptor agonists on treatment-resistant depression - DATRD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002334

Enrollment

Registered

2009-08-15

Start date

2005-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

treatment-resistant depression

Interventions

treatment with dopamine receptor agonist

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: depressed patients, who have significant and moderate depressive symptoms despite at least two adequate trials with antidepressants from different classes

Exclusion criteria

Exclusion criteria: 1) allergy for dopamine agonists, 2) allergy for antidepressants, 3) severe psychotic symptoms, 4) consciousness disturbance, 5) severe hypotension, 6) severe physical disease (heart, lung, liver, kidney, bone marrow, endocrine), 7)peripheral vascular disease, 8) active ulcer, 9) pregnancy, breast-feeding, 10) subjects, whom investigators consider inappropriate

Design outcomes

Primary

Measure	Time frame
Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Rating Scale (MADRS)	—

Secondary

Measure	Time frame
Global Assessment of Functioning (GAF), side effects, FDG-PET, MRI, plasma HVA	—

Countries

Japan

Contacts

Public ContactTakeshi Inoue

Hokkaido University Graduate School of Medicine Department of Psychiatry

011-716-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026